Gastric cancer is one of the most common malignant tumors and ranks second among the malignant tumors of the digestive tract in China. The treatment strategy for gastric cancer is a comprehensive treatment with surgery as the main modality. Chemotherapy is mainly used for unresectable preoperative chemotherapy, intraoperative infusion chemotherapy, adjuvant therapy after resection, treatment of postoperative recurrence and palliative treatment of advanced gastric cancer. Preoperative chemotherapy: preoperative chemotherapy for patients who can be radically resected by clinical evaluation is called neoadjuvant chemotherapy, and for those who cannot be radically resected but become resectable after chemotherapy is called translational chemotherapy. Currently, most neoadjuvant chemotherapy uses a preoperative 3-course chemotherapy regimen, and surgery is performed 3-4 weeks after chemotherapy, usually no more than 6 weeks. Intraoperative intraperitoneal warm perfusion chemotherapy: laparotomy combined with intraoperative intraperitoneal warm perfusion chemotherapy is currently an important treatment for peritoneal implantation of gastric cancer. Postoperative adjuvant chemotherapy: clinically, chemotherapy is usually administered 3-4 weeks postoperatively, either as single agent oral chemotherapy with tegeo (S1) or as a combination regimen (siroda combined with oxaliplatin). Palliative chemotherapy: fluorouracil and its derivatives and platinum drugs are the classical drugs used for palliative treatment of gastric cancer, and paclitaxel drugs as well as targeted drugs have been used in advanced gastric cancer with good results. There are various chemotherapy regimens for gastric cancer. If you need chemotherapy for gastric cancer, you still need to undergo chemotherapy under the guidance of professional doctors’ advice.